Pharmacodynamics, Safety, Tolerability and Pharmacokinetics of CDX-6114 in Patients With Phenylketonuria (PKU)
Status:
Completed
Trial end date:
2020-08-30
Target enrollment:
Participant gender:
Summary
This study is an international, multi-center, randomized, double-blind, placebo-controlled,
two-treatment, two-period cross-over study to evaluate the pharmacodynamics, safety,
tolerability and pharmacokinetics of a single oral dose of CDX-6114 in patients with
phenylketonuria (PKU).